Minocycline oral dosage forms for the treatment of acne

Details Minocycline oral dosage forms for the treatment of acne Minocycline oral dosage forms for the treatment of acne

2007-04-02

2009-06-02

Marschel, Ardin (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

3,10-dihydroxy-2-naphthacene carboxamide or derivative doai

C424S482000, C424S457000, C424S458000, C424S455000, C424S474000, C424S490000, C424S495000, C424S497000, C424S489000, C424S498000

Reexamination Certificate

active

07541347

ABSTRACT:
Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.

REFERENCES:
patent: 3932615 (1976-01-01), Ito et al.
patent: 3957980 (1976-05-01), Noseworthy
patent: 3966922 (1976-06-01), Okamoto et al.
patent: 4086332 (1978-04-01), Armstrong
patent: 4126680 (1978-11-01), Armstrong
patent: 4369172 (1983-01-01), Schor et al.
patent: 4376118 (1983-03-01), Daher et al.
patent: 4443442 (1984-04-01), Skillern
patent: 4701320 (1987-10-01), Hasegawa et al.
patent: 4764377 (1988-08-01), Goodson
patent: 4792448 (1988-12-01), Ranade
patent: 4806529 (1989-02-01), Levy
patent: 4837030 (1989-06-01), Valorose, Jr. et al.
patent: 4925833 (1990-05-01), McNamara et al.
patent: 4935411 (1990-06-01), McNamara et al.
patent: 4935412 (1990-06-01), McNamara et al.
patent: 4960913 (1990-10-01), Szalay et al.
patent: 5007790 (1991-04-01), Shell
patent: 5122519 (1992-06-01), Ritter
patent: 5167964 (1992-12-01), Muhammad et al.
patent: 5188836 (1993-02-01), Muhammad et al.
patent: 5202128 (1993-04-01), Morella et al.
patent: 5209978 (1993-05-01), Kosaka et al.
patent: 5211958 (1993-05-01), Akkerboom et al.
patent: 5217493 (1993-06-01), Raad et al.
patent: 5230895 (1993-07-01), Czarnecki et al.
patent: 5262173 (1993-11-01), Sheth et al.
patent: 5277916 (1994-01-01), Dwyer et al.
patent: 5283065 (1994-02-01), Doyon et al.
patent: 5300304 (1994-04-01), Sheth et al.
patent: 5324751 (1994-06-01), DuRoss
patent: 5348748 (1994-09-01), Sheth et al.
patent: 5413777 (1995-05-01), Sheth et al.
patent: 5459135 (1995-10-01), Golub et al.
patent: 5518730 (1996-05-01), Fuisz
patent: 5554654 (1996-09-01), Yu et al.
patent: 5582837 (1996-12-01), Shell
patent: 5665776 (1997-09-01), Yu et al.
patent: 5674539 (1997-10-01), Tomas
patent: 5776489 (1998-07-01), Preston et al.
patent: 5780049 (1998-07-01), Dickner et al.
patent: 5800836 (1998-09-01), Morella et al.
patent: 5814331 (1998-09-01), Holen
patent: 5834450 (1998-11-01), Su
patent: 5855904 (1999-01-01), Chung et al.
patent: 5908838 (1999-06-01), Gans
patent: 5972389 (1999-10-01), Shell et al.
patent: 6087382 (2000-07-01), Bonner, Jr. et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6165513 (2000-12-01), Dansereau et al.
patent: 6165999 (2000-12-01), Vu
patent: 6194000 (2001-02-01), Smith et al.
patent: 6340475 (2002-01-01), Shell et al.
patent: 6340476 (2002-01-01), Midha et al.
patent: 6429204 (2002-08-01), Golub et al.
patent: 6455583 (2002-09-01), Pflugfelder et al.
patent: 6497902 (2002-12-01), Ma
patent: 6638922 (2003-10-01), Ashley et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 6863830 (2005-03-01), Purdy et al.
patent: 6958161 (2005-10-01), Hayes et al.
patent: 7008631 (2006-03-01), Ashley
patent: 7211267 (2007-05-01), Ashley
patent: 2002/0015731 (2002-02-01), Appel et al.
patent: 2003/0082120 (2003-05-01), Milstein
patent: 2003/0130240 (2003-07-01), Ashley
patent: 2003/0139380 (2003-07-01), Ashley
patent: 2003/0199480 (2003-10-01), Hayes et al.
patent: 2003/0229055 (2003-12-01), Ashley
patent: 2004/0002481 (2004-01-01), Ashley et al.
patent: 2004/0115261 (2004-06-01), Ashley
patent: 2004/0127471 (2004-07-01), Reisberg
patent: 2004/0228912 (2004-11-01), Chang et al.
patent: 2005/0136107 (2005-06-01), Patel et al.
patent: 2005/0148552 (2005-07-01), Ryan et al.
patent: 2006/0293290 (2006-12-01), Wortzman
patent: 2025703 (1990-09-01), None
patent: 2068366 (1992-11-01), None
patent: 2090561 (1993-02-01), None
patent: 0 184 389 (1986-06-01), None
patent: 0 418 565 (1991-03-01), None
patent: 0 558 913 (1992-09-01), None
patent: 2414668 (2005-12-01), None
patent: 02006437 (1990-01-01), None
patent: WO 93/18755 (1993-09-01), None
patent: WO 98/11879 (1998-03-01), None
patent: WO 98/55107 (1998-12-01), None
patent: WO 99/58131 (1999-11-01), None
patent: WO 02/080932 (2002-10-01), None
patent: WO 03/088906 (2003-10-01), None
patent: WO 2004/012700 (2004-02-01), None
patent: WO 2004/078111 (2004-09-01), None
Minocin product insert, Wyeth Pharmaceuticals Inc. Rev Oct. 2005.
Adolfo C. Fernandez-Obregon, Azithromycin for the treatment of acne, International Journal of Dermatology 2000, 39, 45-50.
Gans et al. The Solubility and Complexing properties of Oxytetracycline and Tetracycline II, Journal of the American Pharmaceutical Association, Sci. Ed. 46, No. 10, Oct. 1957.
Sheehan-Dare, et al., “A Double-blind Comparison of Topical Clindamycin and Oral Minocyclin in the Treatment of Acne Vulgaris”, Acta Derm Venereol (Stockh), 70, pp. 534-537.
Ta et al., Effects of Minocycline on the Ocular Flora of Patients with Acne Rosacea or Seborrheic Blepharitis, Cornea vol. 22(6): 545-548,2003.
U.S. Appl. No. 11/695,539, filed Apr. 2, 2007, Mitchell Wortzman.
U.S. Appl. No. 11/695,514, filed Apr. 2, 2007, Mitchell Wortzman.
U.S. Appl. No. 11/695,541, filed Apr. 2, 2007, Mitchell Wortzman.
U.S. Appl. No. 11/695,513, filed Apr. 2, 2007, Mitchell Wortzman.
U.S. Appl. No. 11/474,866, filed May 11, 2007, Mitchell Wortzman.
Fleischer, A.B. et al. Safety and Efficacy of a New Extended-Release Formulation of Minocycline. Cutis 2006; 78 (suppl 4):21-31.
Freedberg, et al., Fizpatrick's Dermatology in General Medicine, 5th Edition, vol. 1, pp. 77-778, 1999.
G. F. Webster, Suppression of Polymorphonuclear Leukocyte Chemotactic Factor Production in Propionibacterium acnes by Subminimal Inhibitory Concentrations of Tetracycline, Ampicillin, Minocycline, and Erythromycin, Antimicrobial Angets and Chemotherapy, May 1982, p. 770-772, vol. 21, No. 5.
Garner et al, Minocycline for Acne Vulgaris: Efficacy and Safety, http://212.49.218.203
ewgenMB/ASP/printDocument.asp, Apr. 14, 2004.
Gilbert et al., Extended-Release Minocycline: Is Efficacy Dose- dependent in the Approved Dose Range?, Poster Presentation for the DUSA Pharmaceuticals, Inc. Medical Conferences and Trade Shows, Hawaii, Mar. 3-9, 2007.
Guy F. Webster, Inflammation in acne vulgaris, Clinical Reviews, Journal of the American Academy of Dermatology vol. 33, No. 2, Part 1, 248-253, Aug. 1995.
H. Akamatsu et al., Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism, Archives of Dermatological Research, 1991, 283: 524-528.
Hirohiko Akamatsu et al., Effect of Doxycycline on the Generation of Reactive Oxygen Species, Acta Derm Venereol (Stockholm), 1992; 72: 179-179.
Is minocycline overused in acne?, Drug and Therapeutics Bulletin. vol. 44 No. 8, 60-62, Aug. 2006.
James Q. Del Rosso, Clinical Significance of Brand Versus Generic Formulations: Focus on Oral Minocycline, Curtis, vol. 77, 153-156, Mar. 2006.
James Q. Del Rosso, et al. Weight-based Dosing of a Novel Antibiotic for Moderate-to-Severe Acne Vulgaris Offers Potential for Improved Safety and Tolerability, www.millennium.com/go/acne, Millennium CME Institute, Inc., 2006.
Jing Li et al, Evidence for Dissolution Rate-Limited Absorption of COL-3, a Matrix Metalloproteinase Inhibitor, Leading to the Irregular Absorption Profile in Rats after Oral Administration, Pharmaceutical Research, Vo. 19, No. 11, 1655-1662, Nov. 2002.
Joseph B. Bilkowski, Treatment of Rosacea With Doxycycline monohydrate, Therapeutics for the clinician, vol. 86, Aug. 2000, 149-152.
K Freeman, Therapeutic focus, Minocycline in the treatment of acne, British Journal of Clinical Pharmacology, vol. 23, 112-123, Mar. 1989.
Kjell Hersle et al., Minocycline in Acne Vulgaris: A Double-Blind Study, Current Therapeutic Research Vo. 19. No. 3, 339-342, Mar. 1976.
L. Illig, Positive Side Effects of Antibiotic and Antimicrobial Substances in Therapy, Infection 7, European Journal for the Clinical Study and Treatment of Infections (1979) Suppl. 6, pp. S 584-588.
Leyden, J. Introduction. Cutis 2006; 78 (suppl 4):4-5.
Lorne M. Golub et al, Tetracyclines Inhibit Connective Tissue Breakdown: New Therapeutic Implications for an Old Family of Drugs, Critical Reviews in Oral Biology and Medicine, 2(2): 297-322 (1991).
M. Schach Von Wittenau et al, The distribution of Tetracyclines in Tissues of Dogs After Repeated Oral Administration, The Journal of Pha

Affiliated with

Also associated with

Rating

Minocycline oral dosage forms for the treatment of acne does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Minocycline oral dosage forms for the treatment of acne, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Minocycline oral dosage forms for the treatment of acne will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4078195